Eli Lilly

News

FDA ramps up its pushback against compounded GLP-1s

In a move that will please Novo Nordisk and Eli Lilly, the FDA sent warnings to 30 telehealth firms, accusing them of illegally marketing GLP-1 drugs.

News

Head to head figurine fights, red and blue

Lilly says orforglipron tops Novo pill in diabetes trial

Lilly's head-to-head trial of oral GLP-1 orforglipron and Novo Nordisk's oral semaglutide in type 2 diabetes raises as many questions as it answers.

News

Black background scattered with red 'SALE' tickets

Novo Nordisk to cut GLP-1 prices in tough US market

Novo Nordisk has turned to pricing as a means to shore up its position in the increasingly competitive market for GLP-1 agonist therapies in the US.

News

Astellas bets on Vir cancer drug, and other licensing deals

Our latest round-up of pharma licensing deals features assets from Vir Biotech, Harbour BioMed, Unnatural Products, Genhouse, and CSL.

News

UK spurs prescribing of obesity jab Mounjaro with GP bonus

Doctors in the UK will be given thousands of pounds in bonus payments from April for prescribing Eli Lilly's weight-loss drug Mounjaro.

News

FDA clears first all-oral combo for first-line CLL treatment

AstraZeneca's Calquence and AbbVie/Roche's Venclexta have become the first all-oral, fixed-duration regimen for newly-diagnosed CLL.

FDA ramps up its pushback against compounded GLP-1s

Lilly says orforglipron tops Novo pill in diabetes trial

Novo Nordisk to cut GLP-1 prices in tough US market

Astellas bets on Vir cancer drug, and other licensing deals

UK spurs prescribing of obesity jab Mounjaro with GP bonus

FDA clears first all-oral combo for first-line CLL treatment

Remepy's hybrid Parkinson's therapy poised for phase 3

Discover a new era of healthcare panel engagement: Grounded ...

Eli Lilly

Editor's Picks